Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.32 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL18095558 | 1.00 | ALDH1A1 (0.33) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL5745817 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL4287600 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL27934780 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL4355857 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL3833376 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL1727596 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL128012 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL140346 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL8009450 | 0.97 | ALDH1A1 (0.35) | ALDH1A1TSHRL3MBTL1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100368805-C | Analysis method of mercapto amine tropine content | JIANGSU PROV INST OF ATOMIC ME (CN) | 2008-02-13 | — | — | CN | claimed |
| CN-1904607-A | Analysis method of mercapto amine tropine content | JIANGSU PROV INST OF ATOMIC ME (CN) | 2007-01-31 | — | — | CN | claimed |
| CN-117942390-A | Solid pharmaceutical composition for oral administration of semaglutin and application thereof | 齐鲁制药有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11957755-B2 | Radiopaque polymers | Boston Scientific Medical Device Limited (IE) | 2024-04-16 | — | — | US | disclosed |
| US-20230285502-A1 | MIXTURES AND FORMULATIONS | CAMURUS AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-11584715-B2 | Crystalline form of sofpironium bromide and preparation method thereof | BOTANIX SB, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11564968-B2 | Formulations containing a somatostatin receptor agonist | CAMURUS AB (SE) | 2023-01-31 | — | — | US | disclosed |
| US-20220168381-A1 | FORMULATIONS CONTAINING A SOMATOSTATIN RECEPTOR AGONIST | CAMURUS AB (SE) | 2022-06-02 | — | — | US | disclosed |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | CAMURUS AB (SE) | 2022-02-08 | — | — | US | disclosed |
| US-20210395197-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| US-11135264-B2 | Formulations containing a somatostatin receptor agonist | CAMURUS AB (SE) | 2021-10-05 | — | — | US | disclosed |
| CN-102579328-B | Pharmaceutical composition for injection | HUANG JIANFENG | 2013-07-10 | — | — | CN | disclosed |
| CN-102579328-A | Pharmaceutical composition for injection | JIANFENG HUANG | 2012-07-18 | — | — | CN | disclosed |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | NOVOGEN RESEARCH PTY LTD (AU) | 2009-09-17 | — | — | US | disclosed |
| CN-100368805-C | Analysis method of mercapto amine tropine content | JIANGSU PROV INST OF ATOMIC ME (CN) | 2008-02-13 | — | — | CN | disclosed |
| CN-1904607-A | Analysis method of mercapto amine tropine content | JIANGSU PROV INST OF ATOMIC ME (CN) | 2007-01-31 | — | — | CN | disclosed |
| US-6815547-B2 | ANTIMICROBIAL AGENTS EFFECTIVE AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, ENTEROCOCCUS | AVENTIS PHARMA S.A. (FR) | 2004-11-09 | — | — | US | disclosed |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | AVENTIS PHARMA S.A. | 2003-09-11 | — | — | US | disclosed |
| US-6602884-B2 | Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | NOVEXEL (FR) | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564968-B2 | Formulations containing a somatostatin receptor agonist | SSTR1, SSTR3, SSTR5 | DPP4 536/4885THRB 315/4885ALDH1A1 3945/4885 |
| US-11584715-B2 | Crystalline form of sofpironium bromide and preparation method thereof | POLR2B, COPB2, FXR1 | DPP4 2198/4885THRB 401/4885ALDH1A1 4690/4885 |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | PHOSPHO1, LIPA, ABHD16A | DPP4 1850/4885THRB 4398/4885ALDH1A1 3730/4885 |
| US-20230285502-A1 | MIXTURES AND FORMULATIONS | PHOSPHO1, LIPA, SGMS1 | DPP4 1857/4885THRB 4152/4885ALDH1A1 2975/4885 |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | DPP4 1770/4885THRB 4708/4885ALDH1A1 1808/4885 |
| US-20090233999-A1 | COMPOSITIONS AND THERAPEUTIC METHODS INVOLVING ISOFLAVONES AND ANALOGUES THEREOF | SHBG, OAT, APOB | DPP4 922/4885THRB 3637/4885ALDH1A1 3385/4885 |
| US-11957755-B2 | Radiopaque polymers | RXFP3, RXFP1, DAGLA | DPP4 3178/4885THRB 1900/4885ALDH1A1 292/4885 |
| US-20210395197-A1 | CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOF | POLR2B, COPB2, FXR1 | DPP4 2198/4885THRB 401/4885ALDH1A1 4690/4885 |
| US-20220168381-A1 | FORMULATIONS CONTAINING A SOMATOSTATIN RECEPTOR AGONIST | SSTR1, SSTR3, SSTR5 | DPP4 536/4885THRB 315/4885ALDH1A1 3945/4885 |
| US-11135264-B2 | Formulations containing a somatostatin receptor agonist | SSTR1, SSTR3, SSTR5 | DPP4 536/4885THRB 315/4885ALDH1A1 3945/4885 |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | DPP4 1770/4885THRB 4708/4885ALDH1A1 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.